Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy

Por Ott, Patrick A.
Publicado no Ann Transl Med (2015)

Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function

Por Ott, Patrick A., Bhardwaj, Nina
Publicado em 2013

Small Molecule Protein Kinase Inhibitors and their Effects on the Immune System: Implications for Cancer Treatment

Por Ott, Patrick A., Adams, Sylvia
Publicado em 2011

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

Por Luke, Jason J, Ott, Patrick A
Publicado em 2014

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

Por Luke, Jason J., Ott, Patrick A.
Publicado no Oncotarget (2015)

Mucosal Melanomas: A Case-Based Review of the Literature

Por Seetharamu, Nagashree, Ott, Patrick A., Pavlick, Anna C.
Publicado em 2010

The secretory IFN-γ response of single CD4 memory cells after activation on different antigen presenting cell types

Por Ott, Patrick A., Tary-Lehmann, Magdalena, Lehmann, Paul V.
Publicado em 2007

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial...

Por Ott, Patrick A., Hodi, F. Stephen, Buchbinder, Elizabeth I.
Publicado no Front Oncol (2015)

HLA-binding properties of tumor neoepitopes in humans

Por Fritsch, Edward F., Rajasagi, Mohini, Ott, Patrick A., Brusic, Vladimir, Hacohen, Nir, Wu, Catherine J.
Publicado em 2014

Combination immunotherapy: a road map

Por Ott, Patrick A., Hodi, F. Stephen, Kaufman, Howard L., Wigginton, Jon M., Wolchok, Jedd D.
Publicado no J Immunother Cancer (2017)

Radiographic Profiling of Immune-related Adverse Events in Advanced Melanoma Patients Treated With Ipilimumab

Por Tirumani, Sree Harsha, Ramaiya, Nikhil H., Keraliya, Abhishek, Bailey, Nancy D., Ott, Patrick A., Hodi, F. Stephen, Nishino, Mizuki
Publicado no Cancer Immunol Res (2015)

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma

Por Luke, Jason J., Donahue, Hilary, Nishino, Mizuki, Giobbie-Hurder, Anita, Davis, Meredith, Bailey, Nancy, Ott, Patrick A., Hodi, F. Stephen
Publicado no Cancer Immunol Res (2015)

Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma

Por Marmarelis, Melina E., Davis, Meredith R., Sethi, Nilay S., Krajewksi, Katherine M., McKay, Rana R., Choueiri, Toni K., Ott, Patrick A.
Publicado no J Immunother Cancer (2016)

Systemic high dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study

Por Min, Le, Hodi, F. Stephen, Giobbie-Hurder, Anita, Ott, Patrick A., Luke, Jason J., Donahue, Hilary, Davis, Meredith, Carroll, Rona S., Kaiser, Ursula B.
Publicado no Clin Cancer Res (2014)

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

Por Chandra, Ravi A, Wilhite, Tyler J, Balboni, Tracy A, Alexander, Brian M, Spektor, Alexander, Ott, Patrick A, Ng, Andrea K, Hodi, F Stephen, Schoenfeld, Jonathan D
Publicado no Oncoimmunology (2015)

A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma

Por Ott, Patrick A., Hamilton, Anne, Jones, Amanda, Haas, Naomi, Shore, Tsiporah, Liddell, Sandra, Christos, Paul J., Doyle, L. Austin, Millward, Michael, Muggia, Franco M., Pavlick, Anna C.
Publicado em 2010

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in pat...

Por Weber, Jeffrey, Grob, Jean-Jaques, Margolin, Kim A, Ascierto, Paolo A, Sznol, Mario, Ott, Patrick A, Lejeune, Chantal, de Pril, Veerle, Ruisi, Mary M, Hodi, F Stephen
Publicado no J Immunother Cancer (2015)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Por Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J.
Publicado no J Immunother Cancer (2016)

PD-1 inhibitor-related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course

Por Nishino, Mizuki, Ramaiya, Nikhil H., Awad, Mark M., Sholl, Lynette M., Maattala, Jennifer A., Taibi, Myriam, Hatabu, Hiroto, Ott, Patrick A., Armand, Philippe F, Hodi, F. Stephen
Publicado no Clin Cancer Res (2016)

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma

Por Ott, Patrick A., Hamid, Omid, Pavlick, Anna C., Kluger, Harriet, Kim, Kevin B., Boasberg, Peter D., Simantov, Ronit, Crowley, Elizabeth, Green, Jennifer A., Hawthorne, Thomas, Davis, Thomas A., Sznol, Mario, Hwu, Patrick
Publicado no J Clin Oncol (2014)